Requisite Capital Management LLC Sells 9,626 Shares of Merck & Co., Inc. $MRK

Requisite Capital Management LLC lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 83.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,924 shares of the company’s stock after selling 9,626 shares during the quarter. Requisite Capital Management LLC’s holdings in Merck & Co., Inc. were worth $204,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MRK. United Financial Planning Group LLC acquired a new stake in shares of Merck & Co., Inc. during the third quarter worth approximately $31,000. Wealth Watch Advisors INC acquired a new position in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $34,000. Dunhill Financial LLC grew its position in Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock worth $35,000 after acquiring an additional 190 shares during the last quarter. Silicon Valley Capital Partners grew its position in Merck & Co., Inc. by 160.5% during the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock worth $35,000 after acquiring an additional 260 shares during the last quarter. Finally, J.Safra Asset Management Corp increased its holdings in Merck & Co., Inc. by 53.6% during the 3rd quarter. J.Safra Asset Management Corp now owns 450 shares of the company’s stock valued at $38,000 after purchasing an additional 157 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Stock Down 0.0%

NYSE MRK opened at $111.36 on Monday. The stock has a market capitalization of $275.03 billion, a P/E ratio of 31.37, a price-to-earnings-growth ratio of 2.51 and a beta of 0.18. Merck & Co., Inc. has a 52 week low of $74.37 and a 52 week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock has a fifty day moving average of $116.00 and a 200-day moving average of $109.36.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts forecast that Merck & Co., Inc. will post 5.16 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MRK shares. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday. Barclays initiated coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price for the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Guggenheim increased their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.